CELU
Celularity Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.68
−8.21%Aug 27, 2026, 13:00 UTC
Celularity Inc. and MuseCell Innovations announced a U.S. manufacturing collaboration for the Dezawa MuseCell platform at Celularity's Florham Park, New Jersey facility.
Source:Aug 25, 2026, 23:59 UTC
Celularity Inc. received a notification letter from Nasdaq on August 21, 2026, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, and its continued delinquency in filing the Form 10-Q for the period ended March 31, 2026.
Source:Jun 30, 2026, 00:00 UTC
Celularity Inc entered into a $1,000,000 secured term loan agreement with the Philip & Daniele Barach Family Trust, bearing interest at 4.0% per annum and maturing in July 2026.
Jun 25, 2026, 00:00 UTC
Celularity Inc. appointed Steven N. Gordon as Chief Operating and Administrative Officer and elected him to the Board of Directors, and promoted K. Harold Fletcher to Chief Legal and Strategy Officer and Corporate Secretary, effective June 19, 2026.
Jun 3, 2026, 00:00 UTC
Celularity Inc appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026.
May 28, 2026, 00:00 UTC
Celularity Inc entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd to resolve default claims, obligating Celularity to pay $500,000 immediately plus five monthly $100,000 installments and assign a $2.5 million principal promissory note from NEXGEL Inc to Helena, with obligations secured by existing collateral.